Understanding the biological role of mutant p53 and its clinical impact requires the
development of a global approach that integrates the structural biology of mutant
proteins, the evaluation of their functional properties, the distribution of
mutations in human cancers, and the correlation between mutations and the clinical and
pathological parameters of cancer. Furthermore, this information should be made available
through an integrated database that uses standardized annotations and allows easy data
retrieval and analysis. This database could be used as a "virtual center of
resources" for information on TP53 mutations and cancers.
The objective of this workshop was to review and discuss the state of the art, the
experimental methods available for such global approaches, and to establish guidelines for
the annotation of mutations into TP53 databases. Given the large mutation dataset
currently available, the TP53 gene may serve as model for such approaches, which may be
extrapolated to other, disease-associated mutant genes.
Aims of Workshop
- Review the current scientific data available on the
specific properties of p53 mutants
- Examine approaches for the identification of changes in
functional activities of p53
- Discuss relationship between specific mutations, prognosis
and therapies
- Initiate the development of a human p53 mutant
functionality database that will be modeled after the TP53 mutation database that is
maintained at IARC
Meeting organizers
Michael Resnick, Chromosome
Stability Section, National Institute of Environmental Health Sciences, NIH, Research
Triangle Park, NC, USA
Pierre Hainaut, Unit of Molecular
Carcinogenesis, International Agency for Research on Cancer, Lyon, France
Participants
Number of speakers: 26
Number of posters: 35
Attendees: 160
Local organizing committee
Pierre Hainaut,
Magali Olivier,
Michelle Wrisez (secretary),
Sponsors
International Agency for Research on
Cancer
National Institute of Environmental
Health Sciences, NIEHS
NIH, Office of Rare Diseases
European Union, 5th Framework
Program on "mutant p53 and Cancer" |
